News

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, reviewed clinical trial and long-term data supporting biologic therapies for HS, emphasizing individualized patient selection and timing of intervention.

New top-line results from the BE BOLD trial provide dermatology clinicians with comparative data on 2 biologic therapies targeting different inflammatory pathways in psoriatic arthritis (PsA).

Meta-analysis finds sexual dysfunction common in asthma and AD, with rates hitting 54% in asthma, prompting better screening.

Sun Pharma's tildrakizumab nears psoriatic arthritis approval as FDA accepts a supplemental biologics license application (sBLA), spotlighting IL-23 benefits for active disease.

Positive phase 3 findings from ADorable-1 suggest lebrikizumab could expand biologic treatment options for younger patients with atopic dermatitis (AD).

Chovatiya discusses treat-to-target goals, biologics, BSA remission, and patient burden in psoriasis.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Experts discuss why alopecia areata should be viewed as a systemic condition with psychosocial consequences beyond visible hair loss.

In case you missed it, this week we had news on deucravacitinib's approval for PsA, AI-based tumor shape analysis in melanoma, QRX003's fast track for Netherton Syndrome, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Experts discuss how clinicians identify the right moment to transition from conventional therapy to biologic treatment in patients with hidradenitis suppurativa (HS).

Jessica DeLuise, PA-C, MHS, CCMS, joins Derm Dispatch to discuss how nutrition and lifestyle intersect with inflammatory skin disease across clinical settings.

Novartis secured the approval through a pharmacokinetic extrapolation strategy rather than a full pediatric RCT, leveraging adult HS trial data and existing pediatric PK modeling from other approved indications.

New case-control study data link tattoo exposure to a higher melanoma risk, prompting fresh scrutiny of ink chemicals and long-term skin safety.

On National Dermatologist Day, EltaMD unveils oil-balancing UV Clear SPF 50, clinically reducing the appearance of blemishes, shine, and pore size. Learn more in this Q&A with Seemal R. Desai, MD, FAAD, and Annie Woo, MD.

Mark Lebwohl, MD, reviews how the AdvanceAD-Tx 487-GEP test identifies which patients are likely to need a JAK inhibitor rather than a biologic.

Although the number of women leaders in Mohs surgery has increased, significant gender disparities remain in leadership roles, productivity metrics, and speaking opportunities.

On National Skin Barrier Day, dermatologists share barrier-saving tips for gentle cleansing, daily sunscreen, smarter product audits, and retinoid adherence.

Recent reviews highlight that melanoma risk associated with occupational UV exposure varies by tumor subtype, anatomical site, and individual susceptibility.

A split-face trial finds adding ivermectin to KTP laser modestly boosts rosacea redness reduction and cuts papules/pustules, without extra downtime.

Compared with topical regimens, Rossi notes PDT provides a shorter recovery window and fewer adherence challenges.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.

Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.

A multicenter trial in China shows ALA-PDT clears Bowen’s disease in 97% with low recurrence, minimal scarring, and high patient satisfaction.

Researchers observed early reductions in acne lesions, with improvements beginning within 5 days of dermocosmetic treatment in patients with acne.

February highlights rare genetic skin diseases, shifting dermatology from supportive care to molecularly targeted therapies.

Results show that bimekizumab achieved significantly higher ACR50 response rates at week 16 than risankizumab in adults with active PsA.

FDA Fast Track boosts hopes for QRX003 lotion in Netherton Syndrome, with early trials showing rapid skin healing and itch relief.

This review of the latest dermatological studies includes insights on pediatric teledermatology rates pre- and post-COVID, a 10-peptide face serum for skin quality, AI-automated disease scoring, and more.